INTRODUCTION
The three isoforms KRAS, NRAS and HRAS belong to a subfamily of 21 kDa monomeric GTPases functioning as signal transducers by cycling between an active, GTP-bound and an inactive, GDP-bound state. The kinetics of GDP dissociation and GTP hydrolysis are modulated in vivo by two classes of proteins. Guanine nucleotide exchange factors (GEFs), such as son of sevenless homolog 1 (SOS1), activate RAS proteins by mediating the exchange of GDP for GTP. GTPase-activating proteins (GAPs), like neurofibromin 1 (NF1), stimulate the low intrinsic GTPase activity, thereby negatively controlling RAS function (1, 2) . In the active state, RAS proteins interact with a number of effectors, including serine/threonine RAF kinases, the catalytic subunits of phosphoinositide 3-kinase (PI3K), phospholipase C1 (PLCE1), RAL guanine nucleotide dissociation stimulator (RALGDS) and Ras association (RA) domain family member 5 (RASSF5). By binding these effectors, RAS regulates multiple signaling pathways that control a variety of cellular functions (3) . RAF-and PI3K-dependent signaling pathways have been most extensively studied. In detail, active RAS can recruit RAF kinases to the plasma membrane promoting their catalytic activation. RAF proteins then phosphorylate the dual-specificity kinases MEK1 (MAP2K1) and MEK2 (MAP2K2), which in turn phosphorylate the extracellular signal-regulated kinases ERK1 (MAPK3) and ERK2 (MAPK1) (4) . GTP-bound RAS also stimulates the activity of PI3K which leads to the production of phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), a second messenger at the plasma membrane. PIP 3 targets the AKT serine/threonine kinases to the membrane, where they become phosphorylated and activated (5) .
Somatic mutations in HRAS, KRAS and NRAS, mainly affecting residues 12, 13 and 61, are found in 30% of human cancers (6 -8) . These alterations result in oncogenic RAS proteins that constitutively bind GTP, as their intrinsic GTPase activity is impaired and/or are insensitive to GAP proteins (9, 10) . Increased RAS signaling also underlies disorders of the neuro-cardio-facial-cutaneous (NCFC) syndrome family, a group of clinically related conditions characterized by facial dysmorphism, congenital cardiac defects, reduced postnatal growth, variable cognitive impairment and tumor predisposition as major clinical features (11 -13) . Besides germline mutations in HRAS, KRAS and NRAS, dysregulated RAS signaling can also be caused by mutations in genes encoding modulators of RAS (PTPN11, SOS1, NF1 and SPRED1), regulators of RAS interaction with effectors (SHOC2) or downstream signal transducers (RAF1, BRAF, MAP2K1 and MAP2K2) (14 -16) .
A number of heterozygous missense mutations of HRAS affecting Gly 12 and Gly 13 , which also occur as somatic changes in human cancers, underlie Costello syndrome (CS; MIM 218040) (17) (18) (19) (20) (21) (22) (23) . CS is characterized by a relatively homogeneous phenotype, including increased prenatal growth, followed by postnatal growth deficiency and severe failure to thrive, variable developmental delay with mental retardation, 'coarse' facial appearance, cardiac defects as well as anomalies of the skin and musculo-skeletal systems and predisposition to certain cancers (24, 25) . A small number of less common missense mutations affecting other codons of the same gene have been identified as germline defects. These lesions have been described in patients with a distinctive, usually attenuated or mild, clinical picture of CS (p.T58I, p.K117R and p.A146T/V) (20, 21, 26, 27) , or specifically occurring in individuals with a predominant muscular phenotype, such as marked weakness, neonatal ventilatory insufficiency, severe myocardial involvement and early lethality as well as some CS typical features (p.Q22K and p.E63K) (22) . These data indicate that the relatively homogeneous and distinctive phenotype characterizing CS can be explained by the narrow mutational spectrum (21) . Of note, while the perturbing role of the p.K117R change on HRAS function has been ascribed to increased GDP/GTP dissociation (27) , as documented previously for other mutations affecting residues involved in the purine ring binding (28) (29) (30) , mutations affecting codons 12 and 13 lead to GAP resistance (9, 10) . Together, these findings imply that the different biochemical behavior of disease-associated HRAS mutants underlies the variable clinical spectrum ranging from classical-to-mild CS and congenital myopathy. Here, we provide further data documenting this idea: the novel HRAS mutant, HRAS E37dup , identified in two unrelated patients with clinical features reminiscent of CS, promotes enhanced growth factor-induced MAPK-and PI3K-dependent downstream signaling resulting from a balancing effect between a profound GAP insensitivity and inefficient binding to effector proteins.
RESULTS
Two different three-nucleotide duplications in HRAS predicting the duplication of glutamate 37 (p.E37dup) of HRAS cause a phenotype resembling CS We sequenced the HRAS coding sequence in two sporadic male patients with a clinical phenotype reminiscent of CS, including 'coarse' face, sparse hair, redundant skin with relatively deep palmar and plantar creases, short stature and psychomotor and mental retardation (Fig. 1A) . The phenotype of the two affected individuals was remarkably similar and characterized by severe mental retardation and pronounced short stature, on the one hand, and relatively mild involvement of the musculo-skeletal system, compared with the classical CS phenotype, on the other hand. We identified the heterozygous condition for a c.110_111þ1dupAGG (patient 1) and c.108_110dupAGA mutation (patient 2) (Fig. 1B) . Both duplications affected the first coding exon of the gene (exon 2), close to the donor splice site, and were predicted to cause duplication of glutamic acid at position 37 (p.E37dup) (Fig. 1B) . Genotyping of parental DNA did not identify the respective HRAS alteration and confirmed paternity, indicating de novo occurrence of mutations. To analyze whether these mutations might affect proper transcript processing, available RNA specimens from patient 2 and an unaffected individual were retrotranscribed for their use in RT -PCR assays. Amplification of the cDNA sequence encompassing the affected exon (exons 1 -3) and sequencing of cloned, amplified products revealed the presence of properly processed mRNA species corresponding to the wild-type (211 bp) and mutated (214 bp) alleles (data not shown). To evaluate whether the c.108_110dupAGA-enhanced HRAS mRNA instability and/ or degradation, and to exclude possible occurrence at low level of in-frame aberrant spliced transcripts, more than 50 clones from the total RNA pools amplified from the patient and control were sequenced. In the former, 22 of the 51 screened clones (43.1%) were represented by the expected wild-type product, whereas 24 (47.1%) harbored the c.108_110dupAGA duplication (Supplementary Material, Figure 1 . Two different in-frame duplications in the first coding exon of the HRAS gene leading to p.E37dup in the GTPase cause a distinctive form of CS. (A) Photographs of patient 1 at the age of 27 months (above) and patient 2 at the age of 5 years and 4 months (below). Note the similar 'coarse' facial features with thick and bushy eyebrows, large mouth with full lips, full cheeks and fleshy earlobes in the two patients. Both had short neck, sparse and thin hair, slightly redundant skin and relatively deep palmar and plantar creases. Note the increased number of creases on palms of patient 2. (B) Details of the sequence electropherograms of HRAS exon 2. Patient 1 is heterozygous for the c.110_111þ1dupAGG and patient 2 for the c.108_110dupAGA mutation of HRAS. Both lesions lead to the duplication of Glu 37 (p.E37dup). Sequences of the wild-type and mutated alleles are given; codons are underlined, and encoded amino acids are indicated below. Exonic sequence is presented in upper case letters and intronic sequence in lower case letters. (C) Schematic representation of HRAS with the distribution of germline disease-causing HRAS amino acid changes. Secondary structural elements of HRAS are shown as green arrows and blue cylinders representing b-sheets and a-helices, respectively. Affected residues are indicated above the HRAS structure. Motifs representing the P-loop and switch I and II regions are indicated by brackets below the protein structure; amino acids (aa) constituting these motifs are given (reviewed in 3). The C-terminus of HRAS contains the membrane-targeting CVLS motif (orange cube).
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Fig . S1 ). The remaining five clones (9.8%) consisted of an aberrantly spliced product missing exon 2, and thus missing of the initial methionine codon. Among the clones carrying the c.108_110dupAGA duplication, 23 (95.8%) were correctly spliced, whereas 1 (4.2%) was improperly spliced, having retained the entire intron 2. This transcript is predicted to generate a short, truncated, functionally impaired protein, which is most likely unstable. Analysis of the amplified cDNA fragment derived from the unaffected individual documented the expected wild-type sequence in the majority of clones (69/ 74, 93.2%) and confirmed the occurrence of the alternatively spliced product with skipping of exon 2 (5/74, 6.8%), ruling out the possibility that this aberrantly spliced mRNA species might be the result of unorthodox transcript processing driven by the CS-causing duplication. Taken together, these data support the idea that the c.108_110dupAGA mutation is predicted to result in the duplication of glutamate 37 (p.E37dup) of HRAS, with no effect on transcript processing. Of note, p.E37dup represents the first germline molecular lesion affecting the switch I region of the HRAS effector loop (Fig. 1C) , which mediates the interaction of the GTPase with various binding partners (31) .
HRAS E37dup potentiates activation of RAS-dependent effector pathways after growth factor stimulation
To explore the functional relevance of the p.E37dup mutation, we first analyzed its consequences on RAF-MEK-ERK and PI3K-AKT signal traffic. The HA-tagged HRAS E37dup protein was ectopically expressed in COS-7 cells, and the phosphorylation status of MEK, ERK and AKT was determined and compared with those of cells expressing either wild-type HRAS, the oncogenic HRAS G12V or the recurrent CS-causing HRAS
G12S
. As a control, we used the dominant negative mutant HRAS S17N , which has been documented to inhibit RAS-mediated signal flow (32, 33) . In cells overexpressing HRAS G12V ( Fig. 2A , lane 5) or HRAS G12S ( Fig. 2A , lane 6) and cultured in medium with 10% serum, the levels of phosphorylated MEK ( Fig. 2A, panel 2) , ERK ( Fig. 2A, panel 4) and AKT ( Fig. 2A, panel 6 ) were similar or slightly elevated compared with those of cells expressing the wild-type protein ( Fig. 2A, lane 2) . In contrast, cells overexpressing HRAS E37dup showed slightly decreased phosphorylation levels ( Fig. 2A, lane 3) , indicating that this mutant negatively influences HRAS-dependent downstream signaling under steady-state growth conditions. Consistent with previous observations (27) (3) . Accordingly, stimulation of serum-deprived cells with specific growth factors can uncover cryptic alterations in RAS-dependent signaling pathways (34) . Therefore, we stimulated serum-starved COS-7 cells expressing each of the HRAS mutant proteins with serum (Fig. 2C) or epidermal growth factor (EGF) (Fig. 2D) and assessed levels of phosphorylated MEK, ERK and AKT. As expected, HRAS G12V ( Fig Together, these data demonstrate that the HRAS E37dup mutant potentiates MAPK and AKT signaling, but only in response to growth factors. 
p.E37dup affects nucleotide dissociation of HRAS
To characterize the in vitro biochemical properties of HRAS E37dup , we first analyzed nucleotide association and dissociation, which are prerequisites for the nucleotide exchange reaction of the GTPase. We measured the association kinetics of fluorescently labeled guanine nucleotide analogues (mantGDP and mantGppNHp) to recombinant HRAS proteins by stopped-flow analysis (35, 36) . The observed rate constants (k obs ) of mantGDP and mantGppNHp to nucleotide-free wild-type HRAS and HRAS E37dup were almost identical (Fig. 3A) . Next, we determined the dissociation kinetics by spectrofluorometry and found that both mantGDP and mantGppNHp dissociated slowly with very similar k obs values from HRAS WT (Fig. 3B ). In contrast, the dissociation rate from HRAS E37dup was markedly increased by 2.3-fold for mantGDP and 8.5-fold for mantGppNHp (Fig. 3B) . Together, these data indicate that duplication of glutamic acid 37 in switch I does not influence HRAS's nucleotide complex formation but facilitates nucleotide release.
To determine GEF-catalyzed GDP dissociation rates, we incubated mantGDP-bound HRAS proteins with the recombinant RasGEF (Cdc25) domain of SOS1 and a 10-fold excess of unlabeled GDP. The very slow intrinsic dissociation rates of bound mantGDP from both HRAS E37dup and HRAS WT were accelerated by about 3 and 4 orders of magnitude, respectively, in the presence of Cdc25 (compare Fig. 3B with C). Nonetheless, SOS1-catalyzed mantGDP dissociation from HRAS E37dup was 2.6-fold decreased compared with HRAS WT (Fig. 3C ). These findings suggest that HRAS E37dup requires RasGEF function to be activated, although the catalytic effect of Cdc25 on the nucleotide exchange of HRAS E37dup is slightly reduced compared with the wild-type protein.
p.E37dup strongly diminishes NF1-catalyzed GTP hydrolysis of HRAS
HRAS is characterized by a low intrinsic GTPase activity that is dramatically stimulated by GAPs. We explored whether the Glu 37 duplication affected the catalytic activity of the GTPase or its responsiveness to GAPs. As shown in Figure 4A , intrinsic GTP hydrolysis for HRAS E37dup was significantly reduced compared with that of the wild-type protein. We then measured HRAS E37dup response to GAP stimulation. GAP-catalyzed GTP hydrolysis can be visualized by using a fluorescently labeled GTP analogue (mantGTP) in a stopped-flow experiment (37, 38) . Mixing of mantGTP-loaded HRAS WT with the catalytic GAP domain of NF1 (NF1-333) led to a rapid initial increase in fluorescence as a result of the association of HRAS WT with NF1-333 (Fig. 4B ). Subsequently, GAP-stimulated hydrolysis reaction was visualized by a decrease in fluorescence (Fig. 4B) . In contrast, no change in fluorescence was observed for the HRAS E37dup mutant, indicating that the protein was able neither to bind NF1-333 nor to undergo NF1-333-stimulated GTP hydrolysis (Fig. 4B ) and supporting the idea that HRAS E37dup accumulates in the GTP-bound form. The switch I region is a point of contact for GAP binding (2) . To quantitatively analyze the interaction of NF1-333 with HRAS WT and HRAS E37dup , we established a new in vitro assay which is based on fluorescence polarization. Recombinant HRAS was preloaded with a fluorescently labeled nonhydrolyzable GTP analogue (mantGppNHp) and titrated with NF1-333 fused to GST (GST-NF1-333). We measured the degree of fluorescence polarization which corresponds to the degree of complex formation between HRAS and NF1-333.
MantGppNHp-HRAS
WT showed a strong increase in fluorescence polarization, even at low GST-NF1-333 concentrations indicating tight binding to NF1-333 (Fig. 4C) . In contrast, much higher GST-NF1-333 concentrations were required to obtain similar changes in fluorescence polarization for mantGppNHp-HRAS E37dup , indicating a strong reduction in binding affinity of the mutant to GST-NF1-333 (Fig. 4C) . Calculation of the dissociation constants (K d ) revealed that the binding affinity of GST-NF1-333 to mantGppNHp-bound HRAS E37dup (K d of 1.2 mM) was 250-fold decreased compared with HRAS WT (K d of 4.5 mM). These data suggest that impaired binding to NF1-333 underlies HRAS E37dup 's insensitivity to NF1-333-catalyzed GTP hydrolysis.
Active HRAS
E37dup inefficiently co-precipitates with RAF1, PIK3CA, RALGDS and PLCE1
On the basis of the evidence that HRAS E37dup exhibits impaired binding to NF1-333 and accumulates in its GTP-bound state, we evaluated binding properties of this mutant to various signaling effectors. Wild-type HA-HRAS or each mutant was overexpressed in COS-7 cells, and, following starvation, cells were stimulated with EGF. Activated HRAS proteins were precipitated from cell extracts using the RAS-binding domain (RBD) of RAF1 (RAF1::RBD; Human
binding of active HRAS WT to RAF1 (Fig. 6A) . In contrast, much higher GST-RAF1::RBD concentrations were required to obtain similar changes in fluorescence polarization of mantGppNHp-HRAS
E37dup
, indicating a strongly decreased binding affinity to RAF1 (Fig. 6A) . We repeated this assay using recombinant binding domains of other HRAS effectors (RALGDS::RA, PLCE1::RA and RASSF5::RBD) and calculated the dissociation constants (K d ) for these HRAS-effector interactions (Fig. 6B) . HRAS E37dup showed strongly increased K d values in !2 orders of magnitude compared with HRAS WT for all effector proteins tested (Fig. 6B) . The binding affinity of HRAS to PIK3CG::RBD was not determined, as this fusion protein could not be isolated at high purity and quantity. From our data, we conclude that HRAS E37dup is characterized by a strongly compromised binding to signaling partners.
DISCUSSION
In .90% of cases, CS is caused by missense mutations affecting Gly 12 (25, 39) . These mutations are associated with a well-recognizable phenotype. So far, only a few patients with missense mutations in other HRAS codons have been described. Among them, individuals with any of the mutations p.T58I, p.K117R and p.A146T/V appear generally less severely affected (20, 21, 26, 27) . Moreover, the p.Q22K and p.E63K amino acid substitutions have been identified in individuals with congenital myopathy and variable features resembling CS (22) , suggesting that patients with uncommon mutations might be underdiagnosed due to their attenuated or atypical phenotype (26) . Here, we reported two sporadic patients with clinical features reminiscent of CS and heterozygous for a different HRAS in-frame duplication predicting the duplication of Glu 37 in the encoded protein. This is the second unusual HRAS mutation for which detailed functional studies have been accomplished, providing important insights into the molecular mechanisms leading to altered HRAS function and dysregulated RAS-dependent signaling pathways in human disease.
The frequently observed amino acid substitutions at residues 12 and 13 result in constitutively active HRAS proteins which positively modulate RAF-MAPK and PI3K-AKT signal flow (3, 12, 34) . Similarly, the rarely detected p.K117R and p.E37dup mutations in HRAS cause enhanced phosphorylation of MEK and ERK (27, this work). Notably, HRAS E37dup was only able to potentiate the activation of downstream pathways upon growth factor stimulation, whereas HRAS K117R activated MEK and ERK after serum deprivation, under basal conditions and upon growth factor stimulation (27) . For HRAS E37dup , we could also demonstrate growth factordependent activation of the PI3K-AKT signaling cascade. Together, these data indicate that individual HRAS mutants, such as HRAS E37dup , depend on growth factors to exert their activating potential, whereas others, e.g. HRAS K117R , HRAS G12V and HRAS G12S , are independent of extracellular stimuli. Of note, in skin fibroblasts of CS-affected patients, the ability of HRAS G12S and HRAS G12V to activate downstream signaling in vivo still appears to be growth factordependent (34) .
As observed for the common CS-causing p.G12S change, p.K117R causes HRAS to accumulate in the active, GTP-bound form (27, 34) . In HRAS
G12S
, this is mainly due to insensitivity to GAP proteins, which usually accelerate the GTPase reaction of wild-type HRAS by 10 5 -fold (9,37,38,40 -42) . In contrast, HRAS K117R is characterized by normal intrinsic and GAP-accelerated GTP hydrolysis but faster GDP/GTP dissociation and reduced GTP binding affinity compared with HRAS WT (27, 43) . These data suggest that perturbed nucleotide binding qualities have similar consequences as impaired GTP hydrolysis (27) . Increased guanine G12S (lane 6) were serum-starved overnight followed by 30 min stimulation with 10 ng/ml EGF. GTP-bound HA-tagged HRAS protein variants were precipitated from cell extracts using GST-RAF1::RBD (A), GST-PIK3CA::RBD (B), GST-PLCE1::RA (C) and GST-RALGDS::RA (D) fusion proteins. Vector controls are shown in lane 1. Precipitated HA-HRAS was detected by immunoblotting using anti-HA antibody (panels 1, 4, 7 and 10). Total amounts of HA-HRAS proteins in the cell lysates are shown in panels 2, 5, 8 and 11. Cellular extracts were probed with anti-GAPDH antibody to control for equal loading (panels 3, 6, 9 and 12). tcl, total cell lysates.
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Human Molecular Genetics, 2010, Vol. 19, No. 5 nucleotide dissociation has also been proposed for the amino acid substitution of alanine for valine or threonine at position 146 (21, 26) . Likewise, p.Q22K seems to have activating effects mainly because of altered GDP/GTP binding (22, 44) . In our in vitro analyses, HRAS E37dup showed a normal nucleotide association rate, whereas the dissociation rate was moderately increased (2.3-fold for mantGDP and 8.5-fold for mantGppNHp), most likely representing marginal alterations.
In marked contrast, we demonstrated complete insensitivity of HRAS E37dup toward NF1-333-stimulated GTP hydrolysis, which was due to the inability of the HRAS mutant to bind NF1-333. Likewise, the two HRAS P34R and HRAS E37N mutants have been shown to inefficiently bind GAPs which resulted in resistance to GAP-catalyzed hydrolysis (45) . Both Pro 34 and Glu 37 are located in the switch I region (Fig. 1C) , which is required for interaction with a variety of RAS-binding partners, including GAPs, GEFs and effectors (46 -48) . Thus, modification of the peptide backbone of the switch I region, such as duplication of Glu 37 , seems to promote an overall rearrangement of this region, leading to a substantially reduced affinity of HRAS mutants to its GAPs. Taken together, our in vitro data strongly suggest that, similar to oncogenic HRAS mutants, HRAS E37dup accumulates in the GTP-bound form, primarily due to its resistance to GAP proteins.
Because of the mild dysregulating effect of the GTP-bound HRAS E37dup on intracellular signaling, we hypothesized that this mutant might exhibit a less efficient capability to activate effectors proteins. Indeed, our in vitro assays revealed drastically decreased binding affinities of HRAS E37dup to RAF1, RALGDS, PLCE1 and RASSF5. These functional data are in agreement with available structural data. The effectorbinding domain of HRAS, also called switch I or effector loop, encompasses residues 30-40 (46) . By introducing effector loop mutations in a constitutively active HRAS mutant (HRAS G12V ), it has been demonstrated that these mutations greatly reduce affinity to most effectors, but yet retaining a significant affinity with some effectors. This is the case of HRAS G12V/T35S and HRAS G12V/D38E which only activate RAF kinases (49, 50) , HRAS G12V/E37G which selectively interacts with RALGDS (50) and HRAS G12V/Y40C which specifically activates the PI3K pathway (51, 52) . Substitution of aspartic acid for alanine at position 38 (HRAS G12V/D38A ), however, abrogates PI3K-dependent downstream signaling (53) . These data strongly indicate that alterations in the effector-binding domain of HRAS can cause a dramatic decrease in the binding affinities to some or all HRAS effectors (54) . Structurally, this is explained by the observation that a stretch of negatively charged residues within the switch I region (Asp 30 , Glu 31 , Asp 33 , Glu 37 and Asp 38 ) creates a negatively charged surface patch required for the interaction with both GAPs and effectors (9) . In line with this, an important role of Glu 37 in stabilizing RAS effector complexes, particularly those with RALGDS and RAF1, has recently been suggested (55) . On the basis of these data, we propose that duplication of Glu 37 strongly disturbs the switch I region of HRAS, resulting in abrogated GAP binding as well as impaired effector association. Thus, whereas resistance of HRAS E37dup to GAPs causes this GTPase mutant to accumulate in the GTP-bound form, transmission of this hyperactivation to downstream signaling cascades appears to be diminished due to decreased effector-binding affinities. Nonetheless, we demonstrated increased growth factor-dependent activation of the MAPK and PI3K-AKT signaling pathways upon HRAS E37dup expression. In general, the activation of HRAS downstream effectors depends on tightly regulated temporal and spatial coincidence of signaling partners which basically occurs upon growth factor stimulation at membrane compartments (5, 56) . We hypothesize that increased convergence of HRAS E37dup with its signaling partners strongly depends on growth factor stimulation and leads to augmented short-time binding, although with low affinity, of GTP-bound HRAS E37dup to its effector proteins resulting in enhanced signal flux. In line with this, EGF-dependent translocation of Noonan syndromeassociated SHP2 mutants to the plasma membrane has been suggested to be required for full stimulation of ERK activity (57) . In summary, we showed that the germ-line p.E37dup mutation in HRAS promotes mildly enhanced signal flow. The molecular mechanism underlying increased HRAS function, however, differs from those documented for oncogenic mutations or previously identified germline HRAS defects. Thus, individual HRAS mutations might differentially influence GTP hydrolysis, kinetics of nucleotide binding and binding properties to regulator (GAPs and GEFs) and effector proteins. This in turn may have different impacts on human development resulting in substantial variation of the clinical outcome.
MATERIALS AND METHODS

Patients and HRAS mutation analysis
Patient 1 was a 5 1 2 -year-old boy, the first child of healthy consanguineous parents (first cousins) of Kurdish origin. At birth, both the parents were 25 years old. The patient was born after an uneventful pregnancy at 39 weeks of gestation by Cesarean section. Birth weight was 3.980 kg (75th -90th centile), length 51 cm (50th -75th centile) and occipitofrontal head circumference (OFC) 37 cm (97th centile). In the neonatal period, dysphagia, severe feeding problems and failure to thrive were recorded. Hypoglycemia was also documented. At the age of 10 months, hypertrophic cardiomyopathy and mild dilatation of the ventricles were diagnosed. Psychomotor and mental developments were delayed: at the age of 15 months, he was not able to turn himself; at the age of 2 1 4 years, he could not walk, and spoke only single words. This boy was first evaluated by one of us (S.M.) at the age of 27 months. His height was 79 cm (,3rd centile, 22.7 SD) and OFC 49 cm (50th centile). Clinical examination revealed a coarse face with thick eyebrows, broad nasal tip, anteverted nares, long philtrum, large mouth with full lips and full cheeks, fleshy earlobes, mild micrognathism (Fig. 1A, upper row) . He had a short neck with redundant skin, deep palmar and plantar creases, hyperextensible fingers and sparse hair with almost no growth. Heavily sweating was reported by parents. He was not dystrophic. At the age of 3 years and 10 months, his height was 88.5 cm (23.7 SD), weight 12.9 kg (3rd centile) and OFC 49.5 cm (25th -50th centile). He had a friendly personality. At the age of 5 1 2 years, his height was 90.3 cm (25 SD), weight 13.2 kg (22.5 SD) and OFC 49.5 cm (15th centile). His unsettled behavior was accompanied by inappropriate laughing and loud crying. Mental retardation was severe with no speech development.
Patient 2 was a 6-year-old male, the second child of healthy non-consanguineous Italian parents. At birth, the mother was 32 and the father 33 years old. He was born at 36 weeks of gestation after an uneventful pregnancy. His birth weight was 3.180 kg (25th centile), body length 48 cm (25th centile) and OFC 34 cm (19th -25th centile). He had mild perinatal distress (meconium-stained amniotic fluid) with respiratory and sucking difficulties at birth. Left renal pyelectasis was also noted in the neonatal period and later confirmed. At the age of 3 weeks, feeding difficulties, cheek dermatitis, mild nasal obstruction and buttock rush were recorded. The patient was first evaluated by one of us (B.D.) at the age of 3 years and 10 months. Stature and weight were below the 5th centile, with relative macrocephaly (50th centile). Psychomotor development was severely retarded. He was able to walk with support after the age of 3 years. He had severe mental retardation. Cardiologic examination did not yet reveal any anomaly, but he had hypertension. Ophthalmologic evaluation disclosed temporal pallor of the optic nerve and strabismus. Clinical examination revealed a coarse face with bushy and thick eyebrows, fleshy earlobes, large mouth with full lips and mildly receding chin. Cheeks were full with an eczematous aspect since the age of 3 months. Scalp hair was sparse. Skin was redundant, especially on the back and hands, which showed an increased number of palmar creases. At the age of 4 years and 3 months, his length was 91 cm (,3rd centile), weight 10.8 kg (,3rd centile) and OFC 50 cm (,9th centile). He was only able to pronounce single monosyllables. He had a friendly personality. An echocardiogram disclosed mild thickening of the ventricular septum. A subsequent evaluation at the age of 5 years and 4 months (Fig. 1A , lower row) revealed eosinophilic esophagitis, likely secondary to regurgitation, which required nasogastric tube feeding. At the age of 6 years, his length was 98 cm (,3rd centile), weight 15.5 kg (,3rd centile) and OFC 50.5 cm (,9th centile). The evaluation of the psychomotor development according to the Griffiths scale (58) was corresponding to 18 months of age. Language was still absent.
We collected blood samples of the two patients and their parents and isolated genomic DNA from lymphocytes by standard procedures. We amplified the coding region including the flanking intronic sequences of the HRAS gene (GenBank accession nos. NM_005343.2 and NM_176795.3) from genomic DNA. Primer sequences are available on request. Amplicons were directly sequenced using the ABI BigDye Terminator Sequencing Kit (Applied Biosystems, Weiterstadt, Germany) and an automated capillary sequencer (ABI 3130; Applied Biosystems). We verified declared relationship by genotyping of both parents and the patient at 10 microsatellite loci.
Ethical approval for this study was obtained, and informed consent for the genetic analysis was received from the parents.
RNA analysis
RNA was isolated from fresh blood leukocytes from patient 2 and a normal individual using RNAWIZ reagent (Ambion, Monza, Italy) according to the manufacturer's instructions. Total RNA (1 mg) was reverse-transcribed using SuperScript II reverse transcriptase (Invitrogen, Karlsruhe, Germany) and oligo dT (Promega, Milan, Italy). Of a total of 20 ml reaction, 1 ml was used as template to amplify wild-type and mutant transcripts by using the exonic primer pair HRAS-cDNAEx1-F (5 0 -GCAGTCGCGCCTGTGAAC-3 0 ) and HRAScDNA-Ex3-R (5 0 -CAATGACCACCTGCTTCCGGTAG-3 0 ). The amplified products were cloned in a pGEM-T easy vector (Promega) and used to transform JM109 competent
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Plasmid construction
We amplified the coding region of wild-type HRAS for the generation of an expression construct by using HRAS-specific PCR primers and HRAS cDNA as a template. Mutated HRAS cDNA inserts [c.34G.A (p.G12S), c.35G.T (p.G12V), c.50G.A (p.S17N) and c.110_111þ1dupAGG (p.E37dup)] were established by PCR-mediated mutagenesis (59) . Purified PCR products were cloned into pENTR/D-TOPO (Invitrogen) according to the protocol provided. Constructs were sequenced for integrity and used for cloning wild-type and mutated HRAS coding regions into plasmid pMT2SM-HA-DEST (N-terminal HA epitope) via left -right reaction following the manufacturer's instructions. Conversion of plasmid pMT2SM-HA into the GATEWAY-compatible vector pMT2SM-HA-DEST has been described elsewhere (60) .
Cell culture and transfection
COS-7 cells were cultured in 100 mm culture dishes in Dulbecco modified Eagle medium (DMEM; Invitrogen) containing 10% serum (Invitrogen) and penicillin-streptomycin (100 U/ml and 100 mg/ml, respectively) (Invitrogen). Using Lipofectamine 2000 Reagent (Invitrogen) according to the manufacturer's protocol, 1.2 Â 10 6 cells were transfected with empty vector pMT2SM-HA-DEST, pMT2SM-HA-DEST-HRAS WT (wildtype), pMT2SM-HA-DEST-HRAS E37dup , pMT2SM-HA-DEST-HRAS G12S , pMT2SM-HA-DEST-HRAS G12V or pMT2SM-HA-DEST-HRAS S17N and incubated overnight. For serum and EGF stimulation, cells were blocked overnight by serum starvation (0.1% serum), followed by incubation in DMEM containing 20% serum or 10 ng/ml EGF (Sigma, Taufkirchen, Germany).
RAS activation assay
The RBD of RAF1 (amino acids 51-131), the RBD of PI3K (PIK3CA) (amino acids 127-314), the RA domain of RALGDS (amino acids 777 -872) and the RA domain of PLC1 (PLCE1) (amino acids 2130-2240) were used to specifically precipitate GTP-bound RAS proteins from cell extracts (61) . Preparation of GST-RBD/RA beads, cell lysis and precipitation of GTP-bound RAS have been described elsewhere (34) . Equal amounts of protein from total cell lysates as well as precipitated bead solutions were separated on 12.5% sodium dodecyl sulfate (SDS) -polyacrylamide gels and subsequently transferred to PVDF membranes. Amounts of total and precipitated active HRAS were detected using peroxidase-conjugated rat monoclonal anti-HA (hemagglutinin) antibody (Roche, Mannheim, Germany; clone 3F10; 1:5000 dilution). For loading control, total cell lysates were probed with mouse anti-GAPDH (Abcam, Cambridge, UK; no. ab8245, 1:5000 dilution). Membranes were incubated with peroxidase-coupled secondary anti-mouse antibody (Amersham Pharmacia Biotech, Freiburg, Germany; no. NA9310; 1:8000 dilution).
Immunoblotting
Twenty-four hours after transfection, cells were cultured as specified and then washed with ice-cold PBS and scraped off in modified RIPA buffer [50 mM Tris-HCl, pH 8.0; 150 mM NaCl; 1% nonidet P40; 0.5% sodium deoxycholate; 0.1% SDS; 1 mM PMSF; 1 mM Na 3 VO 4 ; 10 mM NaF; 1 Complete Mini protein inhibitor cocktail tablet (Roche) per 10 ml]. Cellular biochemical reactions were immediately stopped by freezing lysates in liquid nitrogen, and frozen lysates were stored at 2808C. After thawing on ice, cell debris was sedimented by centrifugation at 18 000g for 10 min at 48C, and protein concentration was determined by using the BCA Protein Assay Kit (Pierce, Bonn, Germany). Proteins from each sample were separated on SDS -polyacrylamide gels and transferred to PVDF membranes. Subsequently, membranes were preincubated in blocking solution (20 mM TrisHCl, pH 7.4; 150 mM NaCl; 0.1% Tween-20; 4% nonfat dry milk) for 1 h at room temperature and then washed in wash buffer (20 mM Tris -HCl, pH 7.4; 150 mM NaCl; 0.1% Tween-20) three times for 5 min. Membranes were incubated in primary antibody dilution buffer (20 mM Tris -HCl, pH 7.4; 150 mM NaCl; 0.1% Tween-20; 5% BSA or 0.5% nonfat dry milk) containing the appropriate antibodies at 48C overnight. Rabbit polyclonal antibodies against MEK1/2 (Cell Signaling Tech., Danvers, MA, USA; no. 9122; 1:1000 dilution), phospho-MEK1/2 (Ser217/221) (Cell Signaling Tech.; no. 9121; 1:1000 dilution), p44/42 MAP kinase (ERK1/2) (Cell Signaling Tech.; no. 9102, 1:1000 dilution), phospho-p44/42 MAP kinase (ERK1/2) (Thr202/Tyr204) (Cell Signaling Tech.; no. 9101, 1:1000 dilution), Akt (Cell Signaling Tech.; no. 9272; 1:1000 dilution) and phospho-Akt (Ser473) (Cell Signaling Tech.; no. 9271; 1:1000 dilution) were used. After being washed in wash buffer (three times, 5 min each), the membranes were incubated with peroxidase-coupled secondary anti-rabbit antibody (Amersham Pharmacia Biotech; no. NA9340V; 1:8000 dilution) for 1 h at room temperature. Finally, sheets were washed three times, 10 min each in wash buffer, and immunoreactive proteins were visualized using the Immobilon Western Chemiluminescent HRP Substrate (Millipore, Schwalbach, Germany).
Recombinant gene expression and protein purification
HRAS
WT and HRAS E37dup were prepared from Escherichia coli using the pGEX expression system as described (35) . Preparation of the nucleotide-free HRAS proteins and their loading with mantGDP or mantGppNHp were achieved as described (36, 38) . Glutathione S-transferase (GST) fusion proteins including RAF1::RBD, PIK3CG::RBD, RASSF5::RBD, RALGDS::RA, PLCE1::RA, Cdc25 (the catalytic domain of SOS1) and NF1-333 (the catalytic GAP domain of NF1) were produced in E.coli. All proteins were purified as described previously (35) .
Kinetics of nucleotide association and dissociation
Association of mantGDP and mantGppNHp (0.2 mM each) with the nucleotide-free RAS proteins (0.3 mM) was measured in 30 mM Tris, pH 7.5, 5 mM MgCl 2 and 3 mM DTE at 258C Human Molecular Genetics, 2010, Vol. 19, No. 5 799 using a Hightech stopped-flow apparatus. Dissociation of mantGDP from the HRAS protein variants (0.3 mM) was triggered by the addition of excess amounts (40 mM) of non-labeled GDP and measured in 30 mM Tris, pH 7.5, 10 mM K-phosphate, 5 mM MgCl 2 and 3 mM DTT at 258C using a Perkin Elmer LS 50 B fluorescence spectrometer at 366 nm (excitation) and 450 nm (emission). Observed rate constants (k obs ) of association and dissociation were obtained by single exponential fitting of the data.
Intrinsic and GAP-stimulated GTP hydrolysis
Intrinsic hydrolysis of the GTP-bound HRAS proteins (30 mM) was analyzed in a buffer containing 30 mM Tris, pH 7.5, 10 mM MgCl 2 and 3 mM DTT at 258C using an HPLC assay as described (36) . At different time points, aliquots were withdrawn from the assay and analyzed by HPLC for their GDP and GTP contents. The relative GTP contents were calculated from the ratio of (GTP)/(GDP þ GTP). Intrinsic GTP hydrolysis rates were fitted by single exponentials. For the determination of the rates of NF1-333-stimulated hydrolysis of mantGTP-bound HRAS proteins, a Hightech stopped-flow spectrophotometer system was used. This system allows to monitor fast biochemical reactions such as RasGAP function. MantGTP-bound HRAS protein (0.2 mM) and the catalytic domain of NF1 (2 mM) were rapidly mixed in a buffer containing 30 mM Tris, pH 7.5, 10 mM K-phosphate, 10 mM MgCl 2 and 3 mM DTE at 258C as described (37, 38) . This method allows to measure the association of NF1-333 with HRASmantGTP and the subsequent NF1-stimulated GTP hydrolysis reaction within the same experiment.
GEF-catalyzed nucleotide dissociation
GEF-catalyzed mantGDP dissociation from HRAS proteins (0.3 mM) was measured in 30 mM Tris/HCl, pH 7.5, 10 mM KP i , 5 mM MgCl 2 and 3 mM DTE at 258C in the presence of 2 mM Cdc25 (the catalytic domain of SOS1) and 40 mM GDP using a Hightech stopped-flow apparatus as described (62) . Observed rate constants (k obs ) were obtained by single exponential fitting of the data.
Effector association
Various RAS effector domains were used to analyze their affinity for mantGppNHp-bound HRAS (0.3 mM) using both Perkin Elmer LS55 and Fluoromax 4 spectrofluorimeters in the polarization mode. Fluorescence polarization is based on the orientation of protein molecules in polarized light. Since orientation is a matter of molecule size, this is an excellent measure to investigate concentration-dependent binding of, e.g., HRAS to GST-fused effector proteins. The GST tag itself contributes significantly to the size of the effector molecules but does not interfere with the chemical properties of the tagged proteins. The experiments were performed in 30 mM Tris/HCl, pH 7.5, 100 mM NaCl, 5 mM MgCl 2 and 3 mM DTE at 258C by titrating in increasing amounts of GST-fused effector proteins. To obtain the dissociation constants (K d ) for the RAS -effector interactions, the concentration-dependent binding curve was fitted using a quadratic ligand-binding equation.
